JPMorgan Chase & Co. increased its stake in shares of Acadia Healthcare Co. (NASDAQ:ACHC) by 20.2% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 6,008,192 shares of the company’s stock after buying an additional 1,008,466 shares during the period. JPMorgan Chase & Co. owned approximately 6.87% of Acadia Healthcare worth $297,706,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of ACHC. Sei Investments Co. boosted its position in Acadia Healthcare by 8.6% in the third quarter. Sei Investments Co. now owns 210,941 shares of the company’s stock valued at $10,452,000 after buying an additional 16,706 shares during the last quarter. Icon Advisers Inc. Co. boosted its position in Acadia Healthcare by 28.9% in the third quarter. Icon Advisers Inc. Co. now owns 16,500 shares of the company’s stock valued at $818,000 after buying an additional 3,700 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Acadia Healthcare by 13.9% in the third quarter. Bank of New York Mellon Corp now owns 583,795 shares of the company’s stock valued at $28,926,000 after buying an additional 71,150 shares during the last quarter. Victory Capital Management Inc. boosted its position in Acadia Healthcare by 3,204.3% in the third quarter. Victory Capital Management Inc. now owns 491,476 shares of the company’s stock valued at $24,353,000 after buying an additional 476,602 shares during the last quarter. Finally, TD Asset Management Inc. boosted its position in Acadia Healthcare by 17.1% in the third quarter. TD Asset Management Inc. now owns 198,050 shares of the company’s stock valued at $9,813,000 after buying an additional 28,900 shares during the last quarter.

Institutional Ownership by Quarter for Acadia Healthcare (NASDAQ:ACHC)

Acadia Healthcare Co. (NASDAQ:ACHC) opened at 37.58 on Tuesday. Acadia Healthcare Co. has a 52-week low of $34.40 and a 52-week high of $69.93. The firm’s market cap is $3.29 billion. The firm’s 50-day moving average is $39.56 and its 200-day moving average is $50.30.

Acadia Healthcare (NASDAQ:ACHC) last issued its quarterly earnings data on Tuesday, November 1st. The company reported $0.58 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.61 by $0.03. Acadia Healthcare had a return on equity of 8.91% and a net margin of 0.22%. The company had revenue of $789.40 million for the quarter, compared to the consensus estimate of $735.59 million. During the same period in the prior year, the company earned $0.62 EPS. The firm’s revenue was up 53.1% on a year-over-year basis. Analysts forecast that Acadia Healthcare Co. will post $2.41 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/29/jpmorgan-chase-co-raises-position-in-acadia-healthcare-co-achc.html.

Several equities analysts have weighed in on the stock. Royal Bank Of Canada lowered their price objective on shares of Acadia Healthcare from $86.00 to $78.00 and set an “outperform” rating on the stock in a research report on Monday, August 1st. RBC Capital Markets reiterated an “outperform” rating and set a $78.00 price objective (down from $86.00) on shares of Acadia Healthcare in a research report on Monday, August 1st. Leerink Swann reiterated a “buy” rating and set a $80.00 price objective on shares of Acadia Healthcare in a research report on Sunday, August 28th. Robert W. Baird lowered their price target on shares of Acadia Healthcare from $67.00 to $66.00 and set an “outperform” rating on the stock in a report on Thursday, September 15th. Finally, Zacks Investment Research upgraded shares of Acadia Healthcare from a “sell” rating to a “hold” rating in a report on Monday, October 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $69.07.

In related news, Director Reeve B. Waud sold 84,208 shares of the firm’s stock in a transaction on Tuesday, September 13th. The shares were sold at an average price of $51.71, for a total value of $4,354,395.68. Following the completion of the transaction, the director now owns 55,673 shares of the company’s stock, valued at $2,878,850.83. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Waud Capital Partners Ii, L.L. sold 54,254 shares of the firm’s stock in a transaction on Tuesday, September 13th. The shares were sold at an average price of $51.71, for a total transaction of $2,805,474.34. The disclosure for this sale can be found here. Insiders own 17.20% of the company’s stock.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc is a provider of behavioral healthcare services. The Company operates in two segments: U.S. Facilities and U.K. Facilities. The Company develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States, the United Kingdom and Puerto Rico.

5 Day Chart for NASDAQ:ACHC

Receive News & Stock Ratings for Acadia Healthcare Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare Co. and related stocks with our FREE daily email newsletter.